Selumetinib
Selumetinib is a pharmaceutical drug with 75 clinical trials. Currently 17 active trials ongoing. Historical success rate of 79.2%.
Success Metrics
Based on 38 completed trials
Phase Distribution
Phase Distribution
33
Early Stage
38
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
74.5%
38 of 51 finished
25.5%
13 ended early
17
trials recruiting
75
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Clinical Trials (75)
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Selumetinib for NF2-Related Schwannomatosis
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
Selumetinib and Olaparib in Solid Tumors
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
AMTEC IIT: Phase 2 Multiarm Study in TNBC
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 75